Study of the effect of Atomoxetine on cognitive symptoms in patients with schizophrenia

Study of the effect of Atomoxetine in comparison with placebo on cognitive symptoms in patients with schizophrenia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20101130005280N31

Enrollment

Registered

2019-12-21

Start date

2019-11-22

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia. ???????? ?????? ? ?????

Interventions

Intervention 1: Intervention group: Patients are given 40 mg of automoxetine is given daily by Tadbir Kala Jam Pharmaceutical Company for 4 weeks and then 80 mg for another 4 weeks. Intervention 2: C

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 2nd Generation Antipsychotic Drug use Lack of dementia Not taking other medicines (except anticholinergics and benzodiazepines) No pregnancy or breastfeeding There is no recent history of drugs (except nicotine) schizophrenic patients during partial recovery

Exclusion criteria

Exclusion criteria: Drug side effects including: abdominal discomfort, loss of appetite resulting in weight loss, dizziness, irritability and mood swings Occurrence of drug interactions with patient medications

Design outcomes

Primary

Measure	Time frame
Cognitive function. Timepoint: Before intervention, end of first and second. Method of measurement: PANSS?Wisconsin? Stroop? Digit Span Questionier.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Fatemeh Behdani

Mashhad University of Medical Sciences

behdanif@mums.ac.ir+98 51 3711 2701

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 12, 2026